Archives: BioMedWire

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on financial and operations results for its second quarter 2024, the period that ended June 30, 2024. Highlights of the report include steady progress made toward key clinical and regulatory milestones on its HeartBeam AIMIGo(TM) System, including the 510(k) submission to the U.S. Food and Drug Administration (FDA); the report also noted that the company has completed two presubmission meetings with the FDA regarding the company’s planned 510(k) submission of its 12-lead synthesis software.

“The second quarter of 2024 was highlighted by new data for the validation of HeartBeam AI, our deep-learning technology, and ongoing progress with anticipated regulatory and clinical milestones for the AIMIGo vector technology platform,” said HeartBeam founder and CEO Branislav Vajdic, PhD, in the press release. “Looking ahead, our optimism continues for the FDA’s clearance of the AIMIGo system, and we are on track for the planned second 510(k) submission.

“We are encouraged by our progress in using artificial intelligence with our vector technology, showcasing the potential of our artificial-intelligence program to improve diagnostic accuracy when a patient is outside of a medical facility,” Vajdic continued. “We also see strength in our product-development pipeline, notably an extended wear patch for detecting heart attacks and complex cardiac arrythmias. This market is estimated to reach $4.8 billion by 2030. Interest from large industry players in partnering continues on key aspects of our portfolio. Our long-term vision is to transform the monitoring and detection of cardiac conditions through our vector-based technology. Our unique approach allows us to deliver the smallest, easiest to use, cable-free 12-lead ECG to patients and their physicians in a variety of form factors and unlock actionable insights on a wide range of cardiac conditions.”

To view the full press release, visit https://ibn.fm/HI2lu

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (“VECG”) technology collects 3D signals of the heart’s electrical activity and converts those signals into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card-sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care, all outside of a medical facility, thus redefining how cardiac health is managed. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the second quarter ended June 30, 2024 (“Q2 2024”). The company also discussed the clinical development progress of Berubicin, its lead program, and TPI 287, its recently in-licensed abeotaxane for the treatment of brain malignancies. CNS Pharmaceutical expects to be able to release final topline data from its potentially pivotal trial of Berubicin in the first half of 2025. The trial is evaluating Berubicin in adult patients with recurrent glioblastoma multiforme (WHO Grade IV) after failure of standard first-line therapy. Additionally, the company plans to engage the U.S. FDA to seek guidance on advancing TBI 287 into a potential registration study of recurrent GBM.

The financial results for Q2 2024 included a net loss of approximately $2.5 million compared to approximately $4.0 million for the comparable period in 2023, R&D expenses of $1.1 million for Q2 2024 versus approximately $2.8 million for Q2 2023, and general and administrative expense of $1.4 million for Q2 2024 compared to approximately $1.2 million for Q2 2023. As of June 30, 2024, CNS Pharmaceuticals had cash of approximately $1.5 million. In addition, the company has raised total gross proceeds of approximately $12.4 million in financing between June 30, 2024, and August 14, 2024. As a result, the company has sufficient cash to fund its operations through the first quarter of 2025.

To view the full press release, visit https://ibn.fm/1GUZ6

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today published its financial results for the second quarter ended June 30, 2024, and provided a business update. Scinai plans to host a webinar to discuss its Q2 2024 results and business update on August 20, 2024, at 11 a.m. EDT/6 p.m. Israel Time.

Recent highlights from Q2 2024 included the signing of an agreement to restructure a $29 million bank loan to equity and plans to regain Nasdaq compliance by August 23, 2024. The company also noted that it has received approximately $600,000 in CDMO work orders since January 2024 and maintains confidence in its guidance for 2024 of $1.25 million in expected sales revenues. The company anticipates revenues from the CDMO business to “increase materially in the coming years.”

In addition, the report noted that the company is “aggressively advancing” the NanoAb preclinical development. Scinai’s Phase 1/2a clinical trial of its anti-IL-17A/F NanoAb (SCN-1) in Plaque Psoriasis, which is expected to include approximately 24 patients, is anticipated to commence in the second half of 2025 with readout in 2026. The report further noted that additional NanoAbs for treating other autoimmune diseases have been discovered and characterized.

The financial results showed that R&D expenses for the six months ended June 30, 2024 (“H1 2024”) reached $2,788,000 compared to $3,449,000 in H1 2023. Marketing, general and administrative expenses for H1 2024 amounted to $1,003,000, compared to $2,332,000 for H1 2023, while the net loss for H1 2024 was $4,481,000 compared to a net loss of $7,277,000 H1 2023. The company ended H1 2024 with cash and cash equivalents and short-term deposits of $3,076,000 compared to $4,870,000 as of June 30, 2023.

To view the full press release, visit https://ibn.fm/mJil0

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today released financial results for its second quarter ended June 30, 2024, and provided a business update. According to the update, results from the company’s completed Phase 2/3 AD study showed that buntanetap significantly improved cognition in patients with early AD. Additionally, data from its Phase 3 PD study revealed that buntanetap led to improvements in both the Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”) and cognition across several PD subpopulations. The company also discussed the filing of patents, team updates, and other achievements.

“The recent months have been productive for our company,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis Bio. “We’ve completed pivotal Phase 2/3 Alzheimer’s and Phase 3 Parkinson’s studies, both of which revealed very encouraging data for buntanetap. Additionally, we’ve introduced a new crystalline form of buntanetap with improved properties, further strengthening our IP portfolio. These milestones position us strongly as we move closer to providing much-needed treatments to patients.”

To view the full press release, visit https://ibn.fm/MgC5E

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), recently had its price target set at $21.00. The price target was issued by Jason Kolbert from EF Hutton on August 13, 2024. At the time of the announcement, Annovis Bio was trading at $7.87. “The overall price target consensus is at $26.00 with high price of $26.00, low price of $26.00, and median price is at $26.00,” the report reads.

To view the full report, visit https://ibn.fm/pXhe9

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

NextPlat (NASDAQ: NXPL), a global e-Commerce provider, has released record financial results for its second fiscal quarter, the period ended June 30, 2024; the results include the consolidation of the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD). Highlights of the report indicate the company experienced a 474% increase in consolidated Q2 revenues, which totaled $17 million, and a record 34.2% quarterly margins; the report noted that the company anticipates reaching $70 million in 2024 annual revenues with additional healthcare services contracts and E-commerce expansion expected to drive the company’s continued growth.

“We are pleased with our second-quarter performance as our healthcare and global e-commerce technology operations continue to produce strong top-line growth and greatly improved margin performance, driven by new 340B services contracts, increased prescription volumes as well as contributions from our recently acquired Outfitter Satellite operations,” said NextPlat executive chair and CEO Charles M. Fernandez in the press release. “Through the strategic combination with Progressive Care and the further expansion of e-commerce sales in North America and China this year, supported by a solid balance sheet, we believe we created a valuable and sustainable growth platform capable of delivering improved operational and financial results for our shareholders in the months ahead.”

To view the full press release, visit https://ibn.fm/FXrya

About NextPlat Corp.

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data-management services in the United States through its subsidiary, Progressive Care Inc. For more information about the company, visit www.NextPlat.com or www.ProgressiveCareUS.com

NOTE TO INVESTORS: The latest news and updates relating to RXMD are available in the company’s newsroom at https://ibn.fm/RXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Evofem Biosciences (OTCQB: EVFM) is reporting on its financial results and corporate update for Q2 2024; the report also included a report on the first half of 2024. Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with Evofem last year; the agreement was amended and restated in July 2024, with a targeted close for later this year.

Highlights of the report show that Evofem saw improved loss from operations by 81% with net product sales increasing 69% in the quarter, totaling $4.2 million compared to $2.5 million in the prior year period. Corporate highlights for the period included the acquisition of SOLOSEC, a commercially attractive, single-dose, FDA-approved oral antibiotic designed to treat two pervasive sexual health infections; the licensing agreement for commercial rights of Phexxi(R) in the Middle East; and a partnership with Hello Alpha, a leading telemedicine company, to add Phexxi to its commercial offering.

“Evofem continues to prove that with a disciplined and committed team we can maneuver through challenges in the market and successfully execute our strategy to expand and diversify our revenue stream,” said Evofem Biosciences CEO Saundra Pelletier in the press release. “Women don’t need more choices, they need better ones, and Evofem will continue to deliver on that promise.”

To view the full press release, visit https://ibn.fm/WWL7r

About Aditxt Inc.

Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drive its mission to “Make Promising Innovations Possible Together.” In December 2023, Aditxt entered into a merger agreement with Evofem under which Aditxt intends to acquire Evofem. The parties reinstated and amended the merger agreement in May 2024 and are working to close the contemplated transaction in the second half of 2024. For more information, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Researchers conducting separate studies published last year all determined that reelin, a protein that helps maintain memory and thinking in the brain, may also protect this important organ from diseases of aging such as Alzheimer’s. The researchers also found that if levels of reelin decrease, the vulnerability of neurons increases.

Professor Li-Huei Tsai of MIT stated that increasing evidence had shown that reelin acted as a protector of the brain. Tsai is also the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Annovis Bio Inc. (NYSE: ANVS) are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Annovis Bio’s lead compound, buntanetap, shows significant enhanced cognitive benefits when combined with GLP-1 agonist dulaglutide in a mouse model
• Buntanetap targets neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases
• GLP-1 agonists, typically used for diabetes, weight loss, and heart conditions, have shown potential in addressing neuroinflammation and neurodegeneration
• The combination treatment results were compelling: While buntanetap alone restored cognitive function to 100% and dulaglutide alone to 80%, the combination restored and also enhanced cognitive function beyond levels seen in healthy controls

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced new preclinical data demonstrating lead compound buntanetap’s potential to synergistically enhance cognition when used in combination with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity(R)) in a mouse model of Alzheimer’s disease (https://ibn.fm/9WpKW).

GLP-1 agonists, such as dulaglutide, are known for their ability to manage blood sugar levels in diabetes patients and are also commonly used for weight loss or heart conditions. However, recent research suggests they also have neuroprotective properties, potentially reducing neuroinflammation and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, is reporting its financial results for the first quarter 2025, or the period ended June 30, 2024. The report also included a status update on the company’s pipeline, including fasedienol for the acute treatment of social anxiety disorder (“SAD”), itruvone for major depressive disorder (“MDD”) and PH80 for vasomotor symptoms, or hot flashes, due to menopause.

Highlights of the financial report indicate research and development expenses totaled $7.6 million for the quarter with general and administrative expenses reported at $4.6 million for the three-month period. The company’s cash, cash equivalents and marketable securities were $108.4 million as of June 30, 2024.

“Building on the success of our PALISADE-2 phase 3 trial of fasedienol, our rapid-onset, nonsystemic pherine nasal spray for the acute treatment of social anxiety disorder, our top priority remains driving forward our U.S. registration-directed PALISADE phase 3 program for fasedienol,” said Vistagen Therapeutics CEO Shawn Singh in the press release. “Our PALISADE-3 phase 3 trial is underway and on track and preparations to initiate our PALISADE-4 Phase 3 trial are progressing as planned. In addition to fasedienol, we are excited about the progress in our other two lead pherine development programs, itruvone for major depressive disorder and PH80 for menopausal hot flashes. With novel nonsystemic mechanisms of action utilizing nose-to-brain neural circuits, each of our pherine clinical-stage programs has potential to transform current treatment paradigms, set new standards of care and improve the lives of millions of underserved individuals.”

To view the full press release, visit https://ibn.fm/hkDWc

About Vistagen Therapeutics Inc.

Vistagen Therapeutics is a late clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on its pioneering approach and deep understanding of nose-to-brain neurocircuitry. Designed exclusively as nasal sprays administered at microgram level doses with novel nonsystemic mechanisms of action, Vistagen’s diversified pipeline of pherine-product candidates rapidly activate chemosensory neurons in the nasal cavity to impact olfactory system and brain neurocircuitry. Favorable safety profiles have been observed in all clinical studies of Vistagen’s pherine-product candidates completed to date. Vistagen’s neuroscience pipeline also includes an oral prodrug with the potential to modulate NMDA receptor activity in multiple neurological conditions, such as levodopa-induced dyskinesia associated with Parkinson’s disease therapy and neuropathic pain. The company is passionate about creating novel and differentiated treatments that set new standards of care for millions of people living with anxiety, depression and other neurological disorders. For more information about the company, please visit www.Vistagen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising innovations, is reporting on the results of its recent annual shareholders’ meeting. According to the announcement, all nine proposed agenda items were successfully passed. Those proposals include the election of directors, the ratification of auditors, and the issuing of shares for Series B-1 and B-2 convertible preferred stock.In addition, a proposed Equity Line of Credit (ELOC) and share increase was approved, among other items.

“I want to thank all of our stakeholders for their participation and continued support,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “We believe that the approval of these proposals will equip us with important tools as we continue to work on meeting certain of our existing obligations and position Aditxt towards achieving our strategic initiatives.”

To view the full press release, visit https://ibn.fm/BCZJY

About Aditxt Inc.

Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drive its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt has a diverse innovation portfolio, which includes the following: Adimune(TM) Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity and allergies; Adivir(TM) Inc., which focuses on enhancing national and population health and impacting public health globally; and Pearsanta(TM) Inc., which delivers rapid, personalized and high-quality lab testing accessible anytime, anywhere, led by its CLIA-certified and CAP-accredited clinical laboratory based in Richmond, Virginia. For more information, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, has expanded the available applications for its platform to account for patient heterogeneity, derisk drug discovery and accelerated pipeline development. The company announced that its findings demonstrate real-world applications of POI’s AI platform to support biomarker discovery, clinical trial optimization and target validation; the platform also offers a proprietary tool that accounts for patient heterogeneity and increases Probability of Technical Success. In addition, Predictive Oncology released a new white paper that discusses these capabilities in greater detail.

“Oncology drug discovery and development are time- and resource-intensive processes that, unfortunately, do not yield high rates of success when considering the relatively small number of compounds that are ultimately approved and made available to cancer patients,” said Predictive Oncology CEO Raymond Vennare in the press release. “Our platform has successfully demonstrated an ability to increase the Probability of Technical Success for these compounds. The ability to accelerate drug development timelines would allow pharmaceutical companies to make critical go/no go decisions, redirect resources or reprioritize R&D efforts to pursue parallel or contingent drug development initiatives. . . . The ability to facilitate biomarker discovery, refine clinical trial optimization and provide decision support, speaks to the broad versatility of our offering. Artificial intelligence is poised to play a rapidly increasing role in pharmaceutical R&D, and we are working to remain at the forefront of this exciting evolution.”

To view the white paper, visit https://ibn.fm/oGJew

To view the full press release, visit https://ibn.fm/YIgVy

About Predictive Oncology Inc.

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence (“AI”) and machine learning (“ML”) to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s proprietary AI/ML platform has been scientifically validated to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. With the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based, drug-discovery solutions, further complemented by its wholly owned Clinical Laboratory Improvement Amendments (“CLIA”) lab and GMP facilities. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the signing of a definitive Loan Restructuring Agreement with the European Investment Bank (“EIB”), its lender. The agreement also included an amendment and restatement to the Finance Contract between the parties.

According to the announcement, an amount equal to approximately €26.6 million (approximately $29 million), including interest accrued to date, owned by Scinai to EIB under the finance contract, will be converted into 1,000 preferred shares, no par value per share, of the company. Following the conversion, the total outstanding amount owed will be €250,000, with the new outstanding loan amount having a maturity date of December 31, 2031. The announcement noted that the preferred shares are convertible (in whole or in part), at the option of the EIB, into a fixed number of ADSs equal to in the aggregate 19.5% of the fully diluted capital of the company as of the closing date.

To view the full press release, visit https://ibn.fm/NfQ7S

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Parkinson’s disease is a progressive condition that affects an individual’s nervous system and the body parts controlled by the nerves. Scientifically speaking, the disease is brought on by neuronal damage caused by too much production of reactive oxygen species.

Damage mainly affects neurons that produce dopamine, which plays a role in cognitive function and motor control. The condition usually gets worse over time, with the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Clene Inc. (NASDAQ: CLNN) are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced a strategic partnership with RxSpark, a platform dedicated to providing affordable prescription medications and healthcare services. According to the announcement, this partnership will enhance the patient’s experience by integrating HealthLynked’s advanced healthcare network with RxSpark’s pharmacy discounts and prescription price comparison tool. Through this exciting integration, HealthLynked members can find savings of up to 90% off their medications, easily manage their prescriptions, and ensure timely access to necessary medications. Key benefits include enhanced prescription management, improved access to affordable medications, streamlined healthcare experience, and cost savings for patients.

“At HealthLynked, we are dedicated to revolutionizing the healthcare experience for our patients. Partnering with RxSpark allows us to provide an integrated solution that addresses a critical aspect of healthcare – medication management. This collaboration will not only enhance our platform’s capabilities but also ensure our patients have access to affordable and timely medications, ultimately improving their health outcomes,” said Dr. Michael Dent, CEO of HealthLynked.

To view the full press release, visit https://ibn.fm/hVgTP

About HealthLynked Corp.

HealthLynked is committed to revolutionizing healthcare on a global scale. Its mission is twofold: to transform the healthcare landscape into a system characterized by exceptional efficiency and superior patient care, and to cultivate a patient-centric network that places individuals at the forefront of their health management. By integrating cutting-edge technology and fostering connectivity, HealthLynked enables patients not just to participate in their healthcare journey, but also to contribute actively to medical research. This innovative approach facilitates the development of treatments for life-altering diseases and accelerates medical breakthroughs.

The company’s network empowers patients with unprecedented control over their medical data, promoting an environment of collaboration where each contribution has the potential to drive significant advancements in health and wellness. Through this pioneering model, HealthLynked is dedicated to securing a healthier future for generations to come, making each patient not only a beneficiary of this system but also a contributor to the global health community.

NOTE TO INVESTORS: The latest news and updates relating to HealthLynked are available in the company’s newsroom at https://IBN.fm/HLYK

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Clene has conducted five Phase 2 clinical trials, three with long-term extensions, and three expanded access programs (with additional studies ongoing) to evaluate the safety and efficacy of CNM-Au8
• The global ALS treatment market is poised for growth, driven by an aging population and limited current treatment options
• CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health, and is at a deficit in neurodegenerative diseases

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). In the recent Emerging Growth Conference 73 on July 17-18, 2024, CEO Rob Etherington and CFO Morgan Brown presented new findings and information about the company and its lead drug candidate, pertinent to current and potential investors.

In the opening of the presentation, Etherington explained that mitochondria play a vital role in cellular metabolism and energy production, and that impaired mitochondrial function is a significant issue in neurodegenerative diseases. Clene’s lead agent, CNM-Au8(R), works by improving cellular energy…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• U.S. Patent No. 12,042,482 specifically addresses traumatic brain injury (“TBI”) treatment with buntanetap, enhancing Annovis Bio’s portfolio that includes various patents and applications for using buntanetap in treating both acute and chronic neurodegenerative diseases and mental illnesses
• Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43
• TBI is one of the major causes of death and disability in the US with annual death rate exceeding 70,000

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced the issuance of a U.S. patent for treating traumatic brain injury (“TBI”) with its lead drug candidate, buntanetap. Initially filed in 2016, the patent covered treatments for various nerve injuries, including TBI, stroke, and spinal cord injuries, but required division into individual patents by the USPTO. Now, U.S. Patent No. 12,042,482, which specifically addresses the treatment of TBI and nerve injury with buntanetap, is successfully added in Annovis Bio’s diverse portfolio covering treatments for multiple acute and chronic neurodegenerative diseases and mental illnesses (https://ibn.fm/tU6FR).

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and protects…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on the results for its first fiscal quarter of 2025, the period ended on June 30, 2024. According to the report, highlights for the company included the company’s collaboration with Pablo Arbelaez, a renowned AI expert and researcher, in the development of the phase 2 clinical trial of IGC-AD1, the lead therapeutic candidate addressing agitation in Alzheimer’s disease. The company also announced that interim data from its phase 2 clinical trial indicates a reduction in agitation in Alzheimer’s, that patient enrollment has begun for its ongoing phase 2 clinical trial investigating IGC-AD1, and that it has extended its Master Loan and Security Agreement by one year.

“The first quarter of fiscal 2025 was marked by significant milestones in our Alzheimer’s research portfolio, underscoring our strategic focus on our innovations,” said IGC Pharma CEO Ram Mukunda in the press release. “The progress in our phase 2 clinical trial for IGC-AD1, highlighted by interim data demonstrating a clinically significant reduction in agitation, validates the immense potential of our lead investigational drug. Additionally, the positive preclinical outcomes for TGR-63 underscore its promise as a transformative therapy for Alzheimer’s, advancing us closer to delivering a novel solution for this critical unmet need. We are strategically positioned to continue expanding our clinical trial footprint and patient enrollment throughout fiscal 2025 as we continue to drive toward commercialization while maximizing operational efficiency and leveraging our unique vertically integrated model.”

To view the full press release, visit https://ibn.fm/vvb1g

About IGC Pharma

IGC Pharma is an artificial intelligence (“AI”)-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer’s disease with the mission to transform patient care with fast-acting, safe and effective solutions. The company’s portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer’s. The IGC-C and IGC-M platforms are advancing in preclinical stages, focusing on tau proteins, early plaque formation and multiple disease hallmarks. IGC Pharma’s lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a phase 2 trial for agitation in dementia associated with Alzheimer’s. Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, the company’s AI models are designed to predict potential biomarkers for the early detection of Alzheimer’s, optimize clinical trials and predict affinity to other neurological disorders, GLP-1, GIP, CB1 receptors, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer’s and related conditions. For more information, visit the company’s website at www.IGCInc.us.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Australia recently launched a countrywide immunotherapy program for infants with peanut allergies. The program is a partnership between the Murdoch Children’s Research Institute and the country’s National Allergy Center of Excellence. This is the first time a countrywide program for peanut allergies is being integrated into mainstream care globally.

The program, whose objective is to safely build tolerance and hopefully achieve remission, is available for babies under 12 months who have been…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Survey indicates sizable proportion of older adult population copes with healthcare costs by skipping treatments, cutting back on basic and essential needs
• Astiva Health is keenly aware of problems faced by underserved senior population
• The company strives to bridge healthcare gaps through proactive, culturally responsive solutions

As growing numbers of the U.S. population reach age 65, the challenge of adequate healthcare becomes even more critical. In fact, a West Health-Gallup survey reports that some elderly are forgoing needed care because of healthcare costs (https://ibn.fm/pJGqA). Astiva Health, a dynamic and innovative Medicare Advantage Prescription Drug (“MAPD”) health plan, is on a mission to meet the challenges faced by underserved aging populations by reshaping the landscape of personalized and comprehensive healthcare.

“The West Health-Gallup survey shows that a sizable proportion of the older adult population copes with healthcare costs by skipping treatments and cutting back on basic and essential needs,” the Gallup report stated. “The avoidance of vital medical care could compound negative health outcomes now and in the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new preclinical data regarding buntanetap, its lead compound. According to the report, the date demonstrates the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease.

The announcement noted that the Alzheimer’s Disease Diagnostics and Therapeutics Market size is projected to reach $7.7 billion this year and grow to $10.1 billion by 2029. Major factors contributing to that growth include the increasing use of biomarkers in Alzheimer’s diagnosis and drug development and the rising prevalence of Alzheimer’s worldwide, the article observed. Active biotech, pharma companies interested in these markets this week include Merck & Co., Inc. (NYSE: MRK), Sanofi (NASDAQ: SNY), Johnson & Johnson (NYSE: JNJ) and Novartis AG (NYSE: NVS).

“In 2018, Annovis Bio published data showing that buntanetap fully restored memory, learning and synaptic potentiation in an Alzheimer’s mouse model,” the article stated. “Building on this research, Annovis recently investigated whether combining buntanetap with the GLP-1 agonist dulaglutide would produce a synergistic effect in the same animal model. The results were compelling: while buntanetap alone restored cognitive function to 100% and dulaglutide alone to 80%, the combination of these two compounds not only restored cognitive function but also enhanced it beyond levels seen in healthy controls.”

To view the full press release, visit https://ibn.fm/Ut8vA

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit www.AnnovisBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, was featured in the latest episode of the BioMedWire Podcast, which is part of a sustained effort by IBN (Investor Brand Network) to provide specialized content distribution via widespread syndication channels. During the episode, Clene CEO and president Rob Etherington talks with IBN’s Carmel Fisher about the company’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”).

“Clene Inc. is focused entirely on improving mitochondrial health and protecting neuron function,” said Clene CEO and president Rob Etherington in the press release. “We’re pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases. . . . Our drug enables the energetic capacity that those muscles require to function and, in the case of ALS, enables the main systems, primarily breathing, to be muscularly sustained so patients potentially have increased rates of survival, as our data suggests.”

To view the podcast, visit https://ibn.fm/a7e9u

To view the full press release, visit https://ibn.fm/KGwBG

About Clene Inc.

Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today reported unaudited financial results for its first quarter of fiscal 2025 ended June 30, 2024 (“Q1 2025”) and provided recent business highlights. In the report, the company noted continued progress towards initiating its Phase 3 multinational study for the CYB003 program in late summer of 2024.

The company reported that it has strengthened its research and development team with two key additions: Dr. Atul R. Mahableshwarkar M.D., DLFAPA, Senior Vice President, Clinical Development, and Dr. Tom Macek, Pharm.D., Ph.D., Senior Vice President, Clinical Development. Cybin also strengthened its intellectual property portfolio with additional patents in support of the CYB004 program. In addition, the report listed upcoming clinical milestones and future studies, including the CYB003, its deuterated psilocybin analog program, and CYB004, its deuterated DMT program.

Financial information for Q1 2025 included cash totaling C$183 million as of June 30, 2024; a net loss of C$15 million for the first quarter ended June 30, 2024, compared to a net loss of C$15 million in the same period last year; and cash-based operating expenses totaling C$16 million in Q1 2025, compared to C$11 million in the prior year quarter. 

“During the recent quarter we continued to move quickly, having achieved meaningful progress on the development of our two lead product candidates: CYB003, our proprietary deuterated psilocybin analog program in development for the adjunctive treatment of Major Depressive Disorder, and CYB004, our proprietary deuterated dimethyltryptamine program in development for the treatment of Generalized Anxiety Disorder. The path towards approval and commercialization for our novel therapeutics is coming into focus as we work efficiently to provide improved outcomes for patients and their families,” said Doug Drysdale, CEO of Cybin.

To view the full press release, visit https://ibn.fm/Xjday

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Scorpius Holdings (NYSE American: SCPX), an integrated contract-development and manufacturing organization (CDMO), has announced the pricing of an underwritten public offering. The offering is comprised of 12,500,000 shares of common stock or prefunded warrants. Each share of common stock or prefunded warrant is offered at $1. According to the announcement, the company has estimated gross proceeds of approximately $12,500,000, before underwriting discounts and offering expenses are deducted; the proceeds will be used for working capital and general corporate expenses. The company also granted the underwriters a 45-day option to purchase up to 1,875,000 additional shares of common stock and/or prefunded warrants to cover any overallotments. ThinkEquity is acting as sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/mO9sY

About Scorpius Holdings Inc.

Scorpius Holdings is an integrated large-molecule contract-development and manufacturing organization (“CDMO”) focused on rapidly advancing biologic and cell-therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information about the company, please visit www.ScorpiusBiologics.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), today released its Q2 2024 financial results. In addition, the company provided recent updates on its CNM-Au8(R) programs evaluating the use of CNM-Au8 for the treatment of ALS and Rett Syndrome. “We are approaching our next FDA interaction focused on the regulatory path forward to potentially bring CNM-Au8 to people living with ALS,” commented Rob Etherington, President and CEO of Clene. “With this imminent timing, we are optimistic about the possibility of submitting a new drug application later this year. Our utmost priority is to help patients and their families for whom time is critical.”

To view the full press release, visit https://ibn.fm/hELDe

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Recently, Syncio entered into a partnership agreement with Vevol Media to streamline e-commerce operations for businesses by integrating different sales channels. Syncio has, for a while now, been streamlining e-commerce operations for merchants on WooCommerce and Shopify. The company is focused on efficiency and simplicity, while Vevol Media specializes in assisting businesses to thrive in the digital marketplace.

Vevol, a leading partner of Shopify, provides a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NextPlat Corp. (NASDAQ: NXPL, NXPLW) are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has released preclinical data from a study of its lead compound, buntanetap. According to the announcement, the study showed the synergistic effect of buntanetap combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity[R]) in enhancing cognition in a mouse model of Alzheimer’s disease.

The news comes as the global Alzheimer’s Disease Therapeutics Market is experiencing significant growth as an escalating aging population along with earlier and more accurate diagnoses contribute to more people facing the disease. The article noted that the sector is projected to exceed $30.8 billion by 2033, with a promising CAGR of 18.8% from 2024 to 2033. Biotech and pharma companies active in the space include Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), GSK plc (NYSE: GSK) and Novo Nordisk A/S (NYSE: NVO).

“In 2018, Annovis Bio published data showing that buntanetap fully restored memory, learning and synaptic potentiation in an Alzheimer’s mouse model,” the article stated. “Building on this research, Annovis recently investigated whether combining buntanetap with the GLP-1 agonist dulaglutide would produce a synergistic effect in the same animal model. The results were compelling: while buntanetap alone restored cognitive function to 100% and dulaglutide alone to 80%, the combination of these two compounds not only restored cognitive function but also enhanced it beyond levels seen in healthy controls.”

To view the full press release, visit https://ibn.fm/joKbE

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit www.AnnovisBio.com.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary Clene Nanomedicine Inc., have submitted new data to the U.S. Food and Drug Administration (“FDA”). The data is regarding CNM-Au8(R) biomarker and clinical efficacy information, including post hoc analyses from two phase 2 clinical trials of CNM-Au8 for the treatment of ALS; the trials were conducted independently.

According to the announcement, this new data is in addition to original data the company has discussed with FDA and is intended to guide the planned FDA Type C interaction; that interaction is expected to take place in the Q3 2024 and will include discussion about an accelerated approval regulatory pathway.

Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”).

“The risk-benefit assessment evidence of CNM-Au8 is strong,” said Clene CEO and president Rob Etherington in the press release. “Our next step is discussing this new CNM-Au8 biomarker and efficacy data with the FDA, with the hope that ALS patients will benefit from this drug, sooner rather than later.”

To view the full article, visit https://ibn.fm/AVplw

About Clene Inc.

Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Astiva Health, a leader in innovative and culturally aware healthcare solutions, today announced the launch of its new Investor Relations website. The launch marks a significant step and milestone in the company’s journey towards becoming a public company. It emphasizes Astiva Health’s commitment to maintaining transparent and effective communication and building strong relationships with investors, stakeholders, and the broader financial community. The platform will offer easy access to detailed company overviews and strategic vision, financial reports and performance metrics, press releases and media coverage, corporate government practices, and upcoming events and presentations. “We are excited to launch our Investor Relations website, a crucial tool that will facilitate transparent communication with our current and prospective investors. As we move towards our goal of becoming a public company, this platform will serve as a central hub for all investment-related information and updates,” commented Dr. Tri T. Nguyen, Co-founder and CEO of Astiva Health.

To view the full press release, visit https://ibn.fm/EddPK

About Astiva Health

Astiva Health is a fast-growing MAPD health plan committed to redefining the standards of personalized and comprehensive healthcare. With a mission to elevate the well-being of individuals, Astiva Health specializes in innovative health plans tailored to meet the unique requirements of its members. The organization prioritizes a culturally responsive approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Astiva Health’s dedication to serving the underserved population is not only fulfilling a critical societal need but also positioning the company to tap into a market segment with significant growth potential. By addressing the diverse healthcare needs of its members, Astiva Health aims to create lasting relationships and contribute to the overall well-being of the communities it serves. Astiva Health invites individuals to join its transformative healthcare experience, where personalized care and lasting well-being take center stage. For more information about Astiva Health and enrollment details, please visit https://astivahealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva are available in the company’s newsroom at https://ibn.fm/Astiva

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is  planning to release its second-quarter 2024 financial report after markets close on Aug. 14, 2024. The company also announced that it has scheduled a conference call and webcast on the same day to discuss the report and provide a company update; the call will begin at 4:30 p.m. ET. To access the call, dial 1.877-407-0789 and then use the conference ID 13747923. An archived replay of the webcast will be available on company website following the event.

To view the webcast, visit https://ibn.fm/E4IZ6

To view the full press release, visit https://ibn.fm/yIbxp

About Longeveron Inc. 

Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B(TM) has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. Lomecel-B development programs have received five separate and distinct FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation and Rare Pediatric Disease designation; and for the Alzheimer’s disease program – Regenerative Medicine Advanced Therapy (“RMAT”) designation and Fast Track designation. To learn more about the company, visit www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting preclinical data regarding its lead compound, buntanetap. According to the announcement, the results show the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease.

Based on data gathered in 2018 showing that buntanetap fully restored memory, learning and synaptic potentiation in an Alzheimer’s mouse model, Annovis recently studied whether buntanetap combined with the GLP-1 agonist dulaglutide produced a synergistic effect in the same animal model. Calling the results “compelling,” the company reported that while buntanetap alone restored cognitive function to 100%, the two compounds together enhanced cognitive function beyond levels seen in healthy controls.

“We are excited to see that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, in the press release. “This synergy is particularly important for enhancing treatment outcomes while minimizing potential side effects. As the field of Alzheimer’s research shifts towards combination therapies, we believe our approach holds great promise for offering more effective treatment options for patients.”

To view the full press release, visit https://ibn.fm/mq0de

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit www.AnnovisBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”)
• CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function
• ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S.

Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform. With a mission to improve underlying mitochondrial health and protect neuronal function, Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”).

At the forefront of Clene’s innovations is CNM-Au8, a gold nanocrystal suspension currently in  development. CNM-Au8 is designed to act as a treatment for ALS, MS, and PD by restoring                neuronal health and function. The drug works by increasing cell energy production and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the process of preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”). The NDA is for PAX-101, an intravenous formulation of suramin that could potentially treat conditions such as Human African Trypanosomiasis and autism spectrum disorder (“ASD”). The process includes having a Type C meeting with the FDA, and then incorporating the outcomes of that meeting, which is a key opportunity for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101.

“PaxMedica’s primary mission is to address the unmet medical needs in ASD,” the article states. “The company is developing PAX-101 for ASD, with a completed phase 2B study showing promising results. Additionally, PAX-102, an intranasal formulation of suramin, is under evaluation for ASD and other neurodevelopmental conditions. The company’s commitment extends to exploring selective APTs that target specific purinergic receptors, potentially offering enhanced therapeutic benefits.”

To view the full article, visit https://ibn.fm/oJcao

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge, anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders. The company’s comprehensive portfolio encompasses a spectrum of conditions, including neurodevelopmental disorders such as autism spectrum disorder (“ASD”) as well as other critical areas within the neurology field. Additionally, the company intends to provide the rest of the world with an additional, reliable source of suramin, the accepted standard of care for Stage 1, Trypanosoma Brucei Rhodesiense. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of the company’s efforts, particularly focused on innovative ASD treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is spotlighted in the latest episode of The Bell2Bell Podcast, released by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. The episode, which featured Annovis Bio founder, president and CEO Dr. Maria Maccecchini, PhD, was recorded live from the Alzheimer’s Association International Conference(R) 2024 (“AAIC”).

During the episode, Maccecchini and IBN’s Stuart Smith discussed the results of the company’s recent phase 3 Parkinson’s study of its lead drug candidate, buntanetap. Maccecchini talked about how the scientific community is reacting to the promising data and what buntanetap could mean for the future of neurodegenerative disease treatment. She also noted Annovis Bio’s plans moving forward, including potential regulatory milestones and upcoming clinical trials designed to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.

“Our phase 3 data indicate that buntanetap has the potential to significantly improve the quality of life for Parkinson’s patients,” said Annovis Bio founder, president and CEO Dr. Maria Maccecchini, PhD, during the episode. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s and Parkinson’s research, underscores the importance of our work and the promise it holds for patients.”

To view the episode, visit https://ibn.fm/ynzI0

To view the full press release, visit https://ibn.fm/YiwqE

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit www.AnnovisBio.com.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is set to present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase and host 1×1 investor meetings. The company’s presentation is scheduled for August 13, 2024, at 11:30 a.m. EST.

To view the live webcast, visit https://ibn.fm/uGo0W

To view the full press release, visit https://ibn.fm/DAs5q

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

TRxADE Health (NASDAQ: MEDS), a pharmaceutical exchange platform provider, and its wholly owned subsidiary Scienture, LLC, a New York based branded specialty pharmaceutical company, today announced changes to Scienture’s executive leadership team. According to the announcement, Narasimhan Mani, Ph.D., MBA, an experienced healthcare professional and a proven health leader with over 25 years of experience in the pharmaceutical industry, has been appointed Scienture’s President. Additionally, Shankar Hariharan, Ph.D., the current President and CEO, will be CEO of Scienture, while Rahul Surana, Ph.D., MBA has been promoted to Executive VP and Chief Operating Officer (“COO”) of Scienture.

“I am pleased to welcome Narasimhan Mani as President to our executive leadership team,” said Hariharan. “He brings significant experience in the core functionalities of Finance, Business, Strategy and Commercial Operations across Sales & Marketing, Market Access, Distribution and P&L Management. This will be an important expansion of capabilities at Scienture as the company moves into its next phase of value-added growth with upcoming launches of its specialty portfolio.”

To view the full press release, visit https://ibn.fm/TSD2v

About TRxADE Health Inc.

TRxADE Health is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The company operates the TRxADE drug procurement marketplace serving a total of 14,500+ members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient-centric telehealth services. For more information on TRxADE Health, visit the company’s website at www.trxadehealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Glioblastoma multiforme is one of the most common brain cancers, primarily affecting an individual’s spine and/or brain. This malignant tumor forms from astrocytes, which support nerve cells. These tumors usually grow and spread very quickly, which creates pressure and destroys healthy tissue.

In 2008, the glioblastoma multiforme genome was characterized by the Cancer Genome Atlas. Since then, scientists have directed their…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

All beneficiaries of Medicare can enroll in Medicare Advantage as an alternative if they need private insurance. Currently, Medicare Advantage makes up over one-half all individuals enrolled in Medicare. Estimates from the Center for American progress show that the Centers for Medicare and Medicaid Services overpays Medicare Advantage plans by between 22% to 39%. This year, overpayments total between $83 billion and $127 billion.

This is despite the fact that there’s no substantial evidence that this program promotes health equity for its enrollees or…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

CEL-SCI (NYSE American: CVM), a cancer immunotherapy company, recently announced the closing of its previously announced best-efforts offering. The transaction involved the sale of 10,845,000 shares of the company’s common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per unit (inclusive of the pre-funded warrant exercise price). The offering raised $10,845,000 in gross proceeds before deductions. CEL-SCI intends to use the net proceeds to fund the continued development of Multikine (its lead investigational therapy), general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering.

To view the full press release, visit https://ibn.fm/W1b9Q

About CEL-SCI Corp.

CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The company’s lead investigational therapy Multikine completed a pivotal Phase 3 clinical trial involving head and neck cancer, for which the company has received Orphan Drug Status from the FDA. The company will be commencing a confirmatory trial for Multikine, with enrollment expected to begin in Q4 2024. CEL-SCI has operations in Vienna, Virginia, and near Baltimore, Maryland. For more information about the company, visit https://cel-sci.com/.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has scheduled a conference call and webcast to discuss its second-quarter 2024 results. According to the announcement, the call is slated to begin at 4:30 p.m. ET on Aug. 14, 2024. HeartBeam executives, including Branislav Vajdic, CEO and founder; Robert Eno, president; and Ravi Malhotra, senior director and corporate controller, will host the call. During the call, the company leaders will discuss second-quarter results, provide regulatory updates, and review ongoing initiatives and anticipated 2024 milestones; the call will also include a question-and-answer period. The company noted that the call will include a presentation, which will also be available on the company website. Those interested in accessing the call can dial 1-844-826-3035 (U.S.) or 1-412-317-5195 (international), and then use conference code 10191273. In addition, a replay of the call will be available. Those wishing to access the replay can dial 1-844-512-2921 (U.S.) or 1-412-317-6671 (international) and then enter the replay pin number 10191273.

To view the presentation, visit https://ibn.fm/ymVR7

To view the webcast, visit https://ibn.fm/aTmFo

To view the full press release, visit https://ibn.fm/Mg5an

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (“VECG”) technology collects 3D signals of the heart’s electrical activity and converts those signals into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card-sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care, all outside of a medical facility, thus redefining how cardiac health is managed. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Cases of neurodevelopmental disorders have increased globally in the last couple of years, with countries such as Italy observing a significant increase in cases of autism, noting that the disorder is more than four times higher in males than females. Autism spectrum disorder affects how individuals interact with others, as well as how they behave, learn and communicate. This disorder is said to have multifactorial origins, with recognized environmental and genetic triggers.

Researchers posit that the period between fetal life through early childhood is the most vulnerable time for neurodevelopmental disorders. They argue that during this…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to PaxMedica Inc. (OTC: PXMD) are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is reporting on its clinical pharmacology study designed to evaluate the uptake of cannabidiol (“CBD”) in a solid formulation that can be delivered as a pill. According to the report, the clinical trial, which was performed with Professor Avi Domb of the Hebrew University, School of Pharmacy, and Professor Elyad Davidson of Hadassah Hospital, involved 12 human participants and compared two solid formulations of CBD with Epidiolex, a U.S. Food and Drug Administration (“FDA”)-approved drug for epilepsy. The company noted that CBD has shown promise in studies on treatment of pain, post-traumatic stress disorder (“PTSD”), head trauma and other indications. However, the oral liquid delivery is not ideal, and the formulations tested by 180 Life Sciences and its collaborators in this study show potential for CBD being delivered by mouth in capsule or pill form. The company is waiting for full results from the study. “If shown via further clinical testing, 180 Life Sciences’ proprietary solid formulation for the delivery of CBD may provide medical professionals with greatly expanded options to prescribe and deliver CBD in a precisely dosed, high-uptake pill format rather than the current liquid format,” said Professor Avi Domb in the press release. “This may have potentially significant commercial market potential by avoiding the complexity associated with unpredictable liquid formulation delivery. Both physicians and patients may have broader acceptance of a solid oral pill format.”

To view the full press release, visit https://ibn.fm/tKhcE

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research and, where appropriate, combination therapy. For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer’s disease (“AD”) involved seven months of dosing and confirms findings from an earlier short-term pilot study. The company reported that results from the study confirm improvements in cognitive function, memory and locomotor activity and show statistical significance in certain behavioral assessments.According to the announcement, InMed is moving forward with additional molecular analyses to better define the mechanisms of action and potential role of INM-901 in the treatment of AD. “We are highly encouraged by the initial data sets from this long-term dosing study, which support the previously observed improvements in behavioral outcomes seen in our initial short-term preclinical Alzheimer’s proof-of-concept study,” said InMed Pharmaceuticals senior vice president of preclinical research and development in the press release. “INM-901 continues to demonstrate potential by targeting multiple biological pathways linked to Alzheimer’s disease and may have potential to address the critical need for effective treatments.”

To view the full press release, visit https://ibn.fm/Ns9Gg

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with its subsidiary BayMedica, the company is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into an exclusive license agreement with Cortice Biosciences Inc.

Through the agreement, CNS Pharmaceuticals has acquired a license as well as the intellectual property rights to a potentially blood-brain-barrier, permeable microtubule inhibitor called TPI 287. The inhibitor is being developed for the treatment of glioblastoma multiforme (“GBM”). In return for the license, CNS Pharmaceuticals will pay Cortice an up-front payment of 616,698 shares of its common stock, as well as the possibility of future success-dependent milestone payments of cash or the company common stock. According to the announcement, Cortice’s TPI 287 is highly synergistic with CNSP’s ongoing potentially pivotal Berubicin program, and the agreement demonstrates the company’s commitment to changing the treatment paradigm in GBM. CNS Pharmaceuticals noted that it anticipates seeking guidance from the U.S. Food and Drug Administration (“FDA”) regarding advancing TPI 287 into a potential registration study for recurrent GBM. In addition, the company announced new corporate brand and website to more closely align with its dedication to addressing the most aggressive type of brain cancer, GBM. “For years, our team has searched for another drug candidate with the same high level of human data-supported therapeutic potential in GBM as Berubicin,” said CNS Pharmaceuticals CEO John Climaco in the press release. “The in-licensing of TPI 287 is a transformational step forward, and we are prepared for the next stage to execute our vision of CNS Pharmaceuticals being the leading biopharma company developing drugs for this devastating and currently inescapably fatal disease.”

To view the full press release, visit https://ibn.fm/QouvY

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Annovis announced in June 2024 that they had filed a composition of matter patent for their new crystal form of buntanetap, along with a provisional patent for the manufacturing process
• The company’s goal is to use this technology to restore brain function and improve the quality of life for patients dealing with neurodegenerative disease such as Alzheimer’s disease
• The worldwide market for Alzheimer’s disease modifying drugs, versus symptomatic drugs, could approach $30 billion by 2030

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders like Alzheimer’s and Parkinson’s, just announced that the U.S. Food and Drug Administration (“FDA”) has given approval for Annovis to switch to a new solid form of buntanetap for their future clinical trials (https://ibn.fm/KfHve).

In June 2024, Annovis announced they had filed a composition of matter patent for their new crystal form of buntanetap, along with a provisional patent for the manufacturing process. To reach this milestone, they conducted extensive bridge studies comparing the old semi-crystalline form with the new…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Scientists have discovered a new mutation that may cause amyotrophic lateral sclerosis to develop. Amyotrophic lateral sclerosis, or ALS in short, is a neurodegenerative illness that weakens an individual’s muscles and affects their physical function.

It starts by degenerating nerve cells in the brain and spinal cord, affecting an individual’s voluntary control of legs and arms. The illness leads to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Clene Inc. (NASDAQ: CLNN) are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is presenting results from its Clear Mind phase 2a clinical trial at the Alzheimer’s Association International Conference(R) (“AAIC”). The conference began on July 28, 2024, and runs through Aug. 1, 2024; the event is being held in person in Philadelphia as well as online. According to the announcement, a Featured Research Session oral presentation discussed findings that show Longeveron’s Lomecel-B improved cognitive function, quality of life and brain volume in the treatment of mild Alzheimer’s disease. The company also noted that the study met key objectives, including advancing data supporting favorable benefit/risk profile, supporting target engagement and providing additional support for the efficacy profile of Lomecel-B. In addition, Lomecel-B minimized the loss in brain volume in areas associated with Alzheimer’s disease. “As a medicinal signaling cell therapy that has multiple potential mechanisms of action to address inflammatory responses in the brain, Lomecel-B offers potential to address the underlying pathology of Alzheimer’s disease without the limitations of previous therapies,” said Longeveron CEO Wa’el Hashad in the press release. “We are very encouraged by the safety profile and efficacy evidence that support the differentiated therapeutic potential of Lomecel-B and lay the foundation for its future clinical development. We’re pleased to connect with the Alzheimer’s community at AAIC 2024 and contribute to the growing body of evidence that fuels the continued development of novel therapeutics for this devastating disease.”

To view the full press release, visit https://ibn.fm/PpvDr

About Longeveron Inc. 

Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B(TM) has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. Lomecel-B development programs have received five separate and distinct FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation and Rare Pediatric Disease designation; and for the Alzheimer’s disease program – Regenerative Medicine Advanced Therapy (“RMAT”) designation and Fast Track designation. To learn more about the company, visit www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is scheduled for Sept. 9–11, 2024, and will be held both virtually and in person in New York City. According to the announcement, virtual participation will be staged simultaneously with company presentations scheduled as live feed or available on-demand. Silo Pharma CEO Eric Weisblum will be presenting during the three-day event. Weisblum’s presentation will include an update on SPC-15, the company’s lead program, which is an intranasal prophylactic treatment for post-traumatic stress disorder (“PTSD”). Weisblum will also provide an overview of Silo Pharma’s novel IP-protected technologies and assets as well as additional investment highlights.

To view the full press release, visit https://ibn.fm/kjXlZ

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions and central nervous system (“CNS”) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug-delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorders. SP-26 is a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (“MS”). Silo’s research and development programs are conducted through collaborations with universities and independent laboratories. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

TRxADE Health (NASDAQ: MEDS), a parent company of pharmaceutical business-to-business (“B2B”) exchange platform, has entered into a business combination with Scienture Inc. in an all-stock transaction. Scienture is a New-York-based pharmaceutical company that develops unique specialty product concepts and solutions. According to the announcement, TRxADE acquired all of Scienture’s assets in exchange for a combination of TRxADE common stock and nonvoting convertible preferred stock. In addition, TRxADE will change its name to Scienture Holdings Inc., with the combined company continuing to trade on the NASDAQ exchange. The boards of directors of both companies have unanimously approved the planned business combination, which will result in a company focused on providing innovative branded, specialty pharmaceutical products designed to enhance the standard of care and add value to patients, caregivers and the healthcare system. “We are very excited about the merger and believe the new combined company will provide the vehicle for our future expansion,” said Scienture president and CEO Shankar Hariharan, PhD., in the press release. “Our mission at Scienture is in developing unique specialty product concepts and solutions that bring enhanced value to patients, caregivers and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments. We are committed to serving patients, physicians and other healthcare stakeholders to attain better health outcomes.”

To view the full press release, visit https://ibn.fm/dZU3G

About TRxADE Health Inc.

TRxADE Health historically focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. The company’s current primary operations are conducted through its wholly owned subsidiary, Integra Pharma Solutions (“IPS”), which is a licensed pharmaceutical wholesaler that sells brand, generic and nondrug products to customers. IPS customers include all healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. For more information about the company, please visit www.TRxADE.com and www.RXIntegra.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

New research has highlighted the increased risk of illnesses spreading to humans from animals. The report by researchers from New York University and Harvard Law School examined common interactions between humans and animals in 15 countries, including the United States.

The researchers discovered numerous examples where viruses could spread to humans, explaining that while zoonotic illnesses, including monkeypox and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Clene’s mission is to transform the treatment of neurodegenerative diseases with a new class of drugs, potentially impacting the lives of millions
• The company’s uniquely structured gold nanocrystals have the remarkable ability to convert critical energetic metabolites in living cells for the production of ATP, the essential energy currency for cellular functions, offering disease combatting capabilities
• Clene is currently preparing for Phase 3 clinical trials of CNM-Au8for ALS and MS, following successful early studies

Xtalks Life Science Podcast recently featured Karen S. Ho, PhD, Vice President of Translational Medicine for Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases. In the episode, host Ayesha Rashid, PhD, discussed Clene’s innovative gold nanocrystal technology and how Dr. Ho is leading the company’s development in diseases like ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), and PD (Parkinson’s Disease).

Clene’s mission is to transform the treatment of neurodegenerative diseases with a unique approach, potentially impacting the lives of millions. They are pioneering a new class of drugs that integrates principles from chemistry, physics, and material science, and applying these to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held Aug. 8–10 in Denver. According to the announcement, CNS Pharmaceuticals has an abstract, titled “Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin,” that has been selected for poster presentation at the conference. CNS Pharmaceuticals chief medical officer Sandra Silberman, MD, PhD, will be presenting. The presentation is slated from 7:15–9 p.m. MT on Aug. 8.

To view the full press release, visit https://ibn.fm/b0PGJ

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its wholly owned subsidiary, Adivir Inc., have signed a second Amending Agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) regarding its previously announced acquisition agreement. A biopharmaceutical company developing treatments and vaccines for infectious diseases and medical countermeasures, Appili has raised C$100 million toward developing its therapeutics since its inception in 2015. According to the amending agreement, the outside date of the acquisition and the date of Appili’s special shareholder meeting has been changed to Sept. 30, 2024. In addition, the deadline for Aditxt to complete necessary financing was changed to Sept. 15, 2024, or such later date as the parties may agree in writing. Through the acquisition, Aditxt will acquire all issued and outstanding Class A common shares of Appili. “Completing the acquisition of Appili Therapeutics will be another milestone in advancing our mission of making promising innovations possible, together,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “The strategic importance of Appili’s work in developing treatments and vaccines for infectious diseases and medical countermeasures could impact millions of people around the globe. We believe Appili’s team and their product portfolio can potentially address some of the most urgent public-health challenges, including antibiotic-resistant infections and bioterrorism threats.”

To view the full press release, visit https://ibn.fm/Ny7zI

About Aditxt Inc.

Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt has a diverse innovation portfolio, including Adimune(TM) Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity and allergies. Adivir(TM) Inc. focuses on enhancing national and population health and impacting public health globally. Pearsanta(TM) Inc. delivers rapid, personalized and high-quality lab testing accessible anytime, anywhere, led by its CLIA-certified and CAP-accredited clinical laboratory based in Richmond, Virginia.

For more information about the company, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis
• On June 27th, PaxMedica will have a Type C meeting with the FDA, pivotal for the progress of PAX-101, their leading drug candidate for autism treatment, within the regulatory framework
• The outcomes of this FDA meeting are crucial, representing a key moment for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101
• The global ASD therapeutics market is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, driven by increasing prevalence, rising awareness, and investment in R&D

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for suramin to treat Human African Trypanosomiasis, a century-old treatment in East Africa. In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an emergency release of suramin, demonstrating its dedication to advancing healthcare solutions.

On June 27th, PaxMedica will have a crucial Type C meeting with the FDA, pivotal for the progress of PAX-101, their leading drug candidate for autism treatment, within the regulatory framework. Type C meetings with the FDA address specific drug development issues like clinical trial design and data…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is reporting on the results of its annual general and special meeting of shareholders; the in-person meeting was held on July 22, 2024, in Toronto, Ontario. According to the report, shareholders were represented in person or by proxy at the meeting. Shareholders elected seven directors for the company, with the directors serving until the next annual meeting or until a successor is elected or appointed; the elected directors include Anthony Durkacz, Zeeshan Saeed, Dr. Lakshmi P. Kotra, Adnan Bashir, Dr. Sanjiv Chopra, Michael (Zappy) Zapolin and Dr. Eric Hoskins. In addition, shareholders reappointed MNP LLP as the company’s auditor; approved a share consolidation resolution; approved a special resolution giving board members power to change the company’s name; passed a special resolution approving and ratifying the company’s articles of amendment; and passed an ordinary resolution authorizing the board to approve the issue of additional Class A multiple voting shares.

To view the full press release, visit https://ibn.fm/NbRdE

About FSD Pharma Inc.

FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. FSD Pharma invented unbuzzd(TM) and spun out its OTC version to Celly Nutrition, a company led by industry veterans. FSD retains ownership of 25.71% of Celly Nutrition Corp. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd until payments to FSD Pharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, FSD Pharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. FSD Pharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical/medical uses. FSD Pharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property. For more information about the company, please visit www.FSDPharma.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent covers methods of treating acute traumatic brain injuries (“TBI”) and preventing nerve cell death with its lead drug candidate, buntanetap. Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. “We are thrilled to achieve this significant milestone for buntanetap,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. “Nerve cell death is a common underlying factor in many brain conditions, beyond just Alzheimer’s and Parkinson’s. Our preclinical studies in TBI and stroke animal models have demonstrated buntanetap’s efficacy in preventing cell death and loss of function, and it is our duty to explore its potential benefits for victims of brain trauma, a prevalent issue in the U.S.”

To view the full press release, visit https://ibn.fm/fbaOW

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS  

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

July 16, 2024, marked the beginning of this year’s Amazon Prime Day, which established a new record in online shopping. The annual two-day sale, which ended on July 17, saw consumers in America spend more than $14 billion.

This year’s figure represents an 11% rise in consumer spending, as 2023’s total consumer spending stood at $12.7 billion. On the first day of the sale, $7.2 billion was spent by…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NextPlat Corp. (NASDAQ: NXPL, NXPLW) are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Evofem Biosciences Inc. (OTCQB: EVFM), a company commercializing innovative products to address unmet needs in women’s sexual and reproductive health, has signed a license and supply agreement for the Middle East rights to Phexxi(R), Evofem’s FDA-approved, hormone-free contraceptive, with private Emirati health care company Pharma 1 Drug Store LLC. Evofem and Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a merger agreement with an anticipated Sept. 2024 closing. According to the Evofem/Pharma 1 agreement, Pharma 1 will obtain and maintain regulatory approvals required to market and sell Phexxi and will also manage the distribution, sales and marketing, pharmacovigilance and other commercial functions required in these countries. Pharma 1 is planning to file UAE regulatory submission for Phexxi as a hormone-free contraceptive this year.The only locally acting contraceptive gel approved by the U.S. Food and Drug Administration (“FDA”), Phexxi is applied before intercourse, maintaining the normal vaginal microbiome with a pH that is naturally inhospitable to sperm as well as certain viral and bacterial pathogens. “The Phexxi licensing agreement for the Middle East is an important milestone as we continue to execute Evofem’s strategy to expand and diversify our revenue stream,” said Evofem CEO Saundra Pelletier in the press release. “We are delighted to partner with Pharma 1, which is uniquely positioned to launch the product and provide women in the UAE and surrounding region with access to hormone-free, nonsystemic birth control that they control and use on demand, only when needed.”

To view the full press release, visit https://ibn.fm/FKBMW

About Evofem Biosciences

Evofem Biosciences is commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The company’s first FDA-approved product, Phexxi(R) (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 prefilled applicators and is applied 0–60 minutes before each act of sex. In December 2023, Evofem entered into a merger agreement with Aditxt under which Aditxt intends to acquire Evofem. The parties amended and restated the merger agreement in July 2024 . The companies are targeting a Sept. 30, 2024, closing. For more information about the company, please visit www.Evofem.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received the minutes of meeting from a recent Scientific Advice (“SA”) with the Paul Erlich Institute, Federal Institute for Vaccines and Biomedicines (“PEI”). According to the announcement, this is the European equivalent to a pre-IND meeting with the U.S. Food and Drug Administration in the United States as well as acceptable guidance for Investigational Medicinal Product Dossier (“IMPD”) filing with the European Medicines Agency (“EMA”). The company noted that the minutes of meeting reflect positive regulatory feedback that can be referenced as drug-development plans move forward for its anti-IL-17A/F nanoAb (SCN-1) in plaque psoriasis phase 1/2a clinical trial. Specifically, the minutes provided clarification for the preclinical toxicology and clinical program for plaque psoriasis first-in-human with intralesional injections for the treatment of patients with mild to moderate plaque psoriasis. The PEI also requested to see data of efficacy in blocking IL-17F; accepted the company’s position that toxicology studies can be conducted in pigs rather than in nonhuman primates; accepted the company’s position to compare the SCN-1 to placebo directly in patients with mild to moderate plaque psoriasis while skipping the need for testing in healthy volunteers; agreed to compare SCN-1 to placebo on the same human subject; and noted that the manufacturing process looks well developed with acceptable controls and specifications.Scinai Immunotherapeutics anticipates the preclinical trial will start in the second half of 2025. “It is encouraging to receive such a supportive regulatory summary for our plans,” said Scinai Immunotherapeutics chief scientist Dr. Tamar Ben-Yedidia in the press release. “The PEI agreed with the unmet need of the patients with mild-to-moderate psoriasis for a better therapy and accepted our pre-clinical and clinical plans that will allow faster development of this product.”

To view the full press release, visit https://ibn.fm/KInAu

About Scinai Immunotherapeutics Ltd. 

Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, derisked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique contract development and manufacturing organization (“CDMO”) providing biological drug development, analytical methods development, clinical cGMP manufacturing, and preclinical and clinical trial design and execution services to early-stage biotech drug-developmet companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen
• These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team.

Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have this strong group of individuals join the Annovis team. “Their expertise and leadership are critical in this pivotal moment in our company, as we continue making strides towards bringing…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health
• Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”)
• The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population
• Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like ALS (amyotrophic lateral sclerosis) and multiple sclerosis (“MS”). In a recent Emerging Growth Conference 73 – Biotech Feature, Clene presented new findings and information pertinent to current and potential investors.

Under the leadership of CEO Rob Etherington, the company focuses on improving mitochondrial health, which is crucial for neurological functions. Mitochondria play a vital role in cellular metabolism and energy production. In neurodegenerative diseases, impaired mitochondrial function is a significant…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Onassis Holdings (OTC: ONSS), a wellness- and biotech-focused holding company, has launched a round of Regulation A+ financing. The company has entered an agreement with Dalmore Group for the fundraising initiative. According to the announcement, Reg A+ funding offers a streamlined method for companies to raise up to $75 million a year from the public. “In aligning with Dalmore Group, Onassis looks to leverage the investment bank’s prowess in capital raising through Regulations A+, CF and D,” stated the announcement. “Since 2021, Dalmore has on-boarded over 270 Reg A+ issuers, establishing itself as a leader in Reg A+ financing services. With over 16 years of experience and deep relationships in multiple financial markets, Dalmore provides strategic partnerships with experts in marketing and PR, syndication partnerships with several Reg A+ marketplace platform distribution partners, and secondary trading solutions for their Reg A+ issuers.”

To view the full press release, visit https://ibn.fm/5Xxrr

About Onassis Holdings Corp.

Onassis Holdings Corp is a wellness and biotech holding company, specializing in healthcare, technology, and the epigenetic reprogramming for rejuvenation. To learn more about the company, visit www.Ananda-Labs.bio.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant tumors.

The researchers found that one skull, which belonged to a female about 50 years of age, had healed injuries on the cranium that may have been made by a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market following NASDAQ rules, included the issue and sale of 2,236,026 shares of LGVN Class A common stock (or common stock equivalents in lieu thereof). The shares were offered at a purchase price of $4.025 per share. The company also closed on a concurrent private placement involving the issue of unregistered warrants to purchase up to 2,236,026 shares of Class A common stock. The unregistered warrants have an exercise price of $3.90 per share and are immediately exercisable for 24 months following the date of issue. The company received an estimated $9 million in gross proceeds from the offering, before the deduction of fees and expenses. Longeveron anticipates using the funds for ongoing clinical and regulatory development of Lomecel-B(TM) as well as capital expenditures, working capital and other general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

To view the full press release, visit https://ibn.fm/f9CL3

About Longeveron Inc. 

Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B(TM) has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. Lomecel-B development programs have received five separate and distinct FDA designations: for the HLHS program, Orphan Drug designation, Fast Track designation and Rare Pediatric Disease designation; for the Alzheimer’s disease program – Regenerative Medicine Advanced Therapy (“RMAT”) designation and Fast Track designation. To learn more about the company, visit www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is inviting investors to a live webinar. Scheduled for July 25, 2024, at 4:15 p.m. ET, this exclusive event will be hosted by RedChip Companies. During the webinar, Nutriband Chairman and President Serguei Melnik and CEO Gareth Sheridan will share insights into the company’s current operations and upcoming milestones.

To register for the free webinar, visit https://ibn.fm/ZZkgn

To view the full press release, visit https://ibn.fm/xnDGN

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into definitive agreements for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per unit in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Silo Pharma will issue unregistered warrants to purchase up to 763,638 shares of common stock at an exercise price of $2.75 per unit. The warrants will be immediately exercisable upon issuance and will expire five years following the date of issuance. The offering is expected to close on or about July 22, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $2.1 million before deductions. Silo Pharma plans to use the net proceeds from the offering for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

To view the full press release, visit https://ibn.fm/gfvm1 

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions and central nervous system (“CNS”) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug-delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorders. SP-26 is a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two pre-clinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (“MS”). Silo’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. For more information about the company, visit http://www.silopharma.com/. 

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

A new survey has determined that the share of employers who still provide health benefits to retirees has been decreasing over time, reaching 21% as of last year. The survey was carried out by Kaiser Family Foundation (KFF), a leading health policy organization in the United States.

The survey’s objective was to examine the extent to which states were offering health benefits to eligible retirees under Medicare, via…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients
• Following the announcement of these positive results, the company’s stock price surged by 76%
• The data revealed that while 12% of Parkinson’s Disease patients showed cognitive decline, buntanetap not only halted this decline but also led to improvements
• Annovis held a webcast to go over the results in more depth, which is available for replay on the company’s website

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease and Parkinson’s Disease, has released new data from its Phase III study of buntanetap for early Parkinson’s Disease. The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients (https://ibn.fm/5ZqlC).

Following the announcement of these positive results, the company’s stock price surged by 76%. This remarkable increase reflects strong investor confidence in buntanetap’s potential to address critical unmet needs in neurodegenerative disease treatment (https://ibn.fm/ZctmR). The trial results…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into a Device and CMC Development Master Plan with medical technology provider Resyca BV. A joint venture between Bespak Group and Medspray Pharma BV, Resyca manufactures the formulation-specific microchip-based spray system that Silo has chosen for its lead candidate SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (“PTSD”). According to the announcement, the Device and CMC Development Master Plan is intended to support the development, clinical formulation, and stability of a previously announced investigational new drug (“IND”)-enabling, large animal GLP (Good Laboratory Practice) study of SPC-15. “The patented nasal spray system uses cutting-edge nose-to-brain drug dispersion, a delivery method that transports the molecules to the brain directly, bypassing the blood-brain barrier,” said Eric Weisblum, CEO of Silo Pharma. “For SPC-15, we believe this delivery method could increase the drug’s concentration in the brain to deliver a faster onset of therapeutic benefit and optimized safety for PTSD patients.”

To view the full press release, visit https://ibn.fm/j41NZ

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions and central nervous system (“CNS”) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug-delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorders. SP-26 is a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two pre-clinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (“MS”). Silo’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. For more information about the company, visit http://www.silopharma.com/.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS
• Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a treatment for ALS via the accelerated approval process
• The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and protecting neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), have revealed plans to submit a briefing book to the U.S. Food and Drug Administration (“FDA”) by July 13. This submission precedes a granted Type C interaction scheduled for the third quarter of 2024, aimed at obtaining FDA feedback on the potential pathway for a new drug application (“NDA”) for CNM-Au8 as a treatment for ALS via the accelerated approval process (https://ibn.fm/icmDr).

CNM-Au8, Clene’s primary therapeutic asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Neurodegenerative diseases often involve multiple pathogenic factors leading to neuronal death, with mitochondrial dysfunction and NAD+ decline being…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is presenting at the 73rd Emerging Growth Conference, scheduled for July 17-18, 2024. Clene’s presentation is slated to begin at 4:45 p.m. EDT on July 18, with Rob Etherington, Clene’s President and CEO, and Morgan Brown, Clene’s CFO, giving the presentation.

To view the full press release, visit https://ibn.fm/kt4FO

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that has been identified to occur at different levels of severity. Patients with this disorder are sometimes misdiagnosed, because its symptoms overlap with other disorders.

It is said that women are less likely to be accurately diagnosed with autism during their lifetimes, with most being misdiagnosed with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to PaxMedica Inc. (NASDAQ: PXMD) are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, along with its wholly owned subsidiary Adifem Inc., and Evofem Biosciences Inc. (OTCQB: EVFM) have amended and restated their previously announced merger agreement. According to the announcement, the amended and restated agreement addresses several issues, including preclosing matters such as interim financing needs that are critical for Evofem’s future success and substituting cash for Aditxt’s common stock as the consideration for Evofem’s common stock in the merger. The announcement also noted that Aditxt and Evofem are working to close the transaction in the second half of 2024. Several closing conditions need to be met before this can happen, including Aditxt securing the necessary funding. The announcement included a mention of Evofem’s recent acquisition of SOLOSEC(R)(secnidazole) 2g oral granules from Lupin Limited. “The acquisition of SOLOSEC marks an important milestone in Evofem’s evolution,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “We believe that SOLOSEC is a valuable asset that diversifies Evofem’s portfolio and has the potential to accelerate its evolution into a dynamic global women’s health business that addresses significant health challenges. Our commitment to supporting the expansion of Evofem’s portfolio with additional products and broadening its market reach domestically and internationally exemplifies how the Aditxt model operates. Our confidence in Evofem’s potential has only strengthened, and we firmly believe that, if supported by the right resources, they will drive significant advancements in women’s health.”

To view the full press release, visit https://ibn.fm/o7z0N

About Aditxt Inc.

Aditxt is is a social innovation platform dedicated to discovering, developing, and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to “Make Promising Innovations Possible Together.” The social innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model democratizing innovation, ensuring every stakeholder’s voice is heard and valued, empowering collective progress.

Aditxt has a diverse innovation portfolio, including Adimune™, Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity, and allergies. Adivir™, Inc. focuses on enhancing population health, impacting public health globally, and Pearsanta™, Inc. delivers rapid, personalized, and high-quality lab testing accessible anytime, anywhere, at their CLIA-certified and CAP-accredited clinical laboratory based in Richmond, VA.

For more information, please visit https://ibn.fm/9Gggb

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, is announcing a strategic partnership with HC Smart, Inc., a national telemedicine provider. The partnership, set to go live within the next four weeks, is expected to extend HealthLynked’s telemedicine services across the U.S. as well as significantly enhance the company’s offerings and accessibility. The announcement stated that the collaboration will integrate HC Smart’s advanced telemedicine capabilities into HealthLynked’s existing platform, providing nationwide coverage to all HealthLynked members. This initiative will offer HealthLynked Network members access to high-quality healthcare from the comfort of their homes by enabling reduced-cost telemedicine consultations as part of HealthLynked’s membership program. “The healthcare landscape is rapidly evolving as patients demand more affordable and convenient health solutions. Traditional methods of seeing a provider often involve numerous value-eroding steps, such as finding a doctor that is located nearby, making an appointment, gathering medical records, and ensuring the doctor accepts their insurance. HealthLynked has addressed these pain points by simplifying the process of finding a doctor, booking appointments, and managing medical records. With the expansion of our telemedicine service, we are increasing the value-capturing solutions that allow patients to see a healthcare provider more conveniently and at a lower cost. Unlike other telemedicine providers, HealthLynked connects in-office appointments with telemedicine visits, allowing patients to seamlessly share their care with local healthcare providers after a remote consultation,” commented Dr. Michael Dent, CEO of HealthLynked.  

To view the full press release, visit https://ibn.fm/j5pqP

About HealthLynked Corp.

HealthLynked is committed to revolutionizing healthcare on a global scale. Its mission is twofold: to transform the healthcare landscape into a system characterized by exceptional efficiency and superior patient care, and to cultivate a patient-centric network that places individuals at the forefront of their health management. By integrating cutting-edge technology and fostering connectivity, HealthLynked enables patients not just to participate in their healthcare journey, but also to contribute actively to medical research. This innovative approach facilitates the development of treatments for life-altering diseases and accelerates medical breakthroughs.

The company’s network empowers patients with unprecedented control over their medical data, promoting an environment of collaboration where each contribution has the potential to drive significant advancements in health and wellness. Through this pioneering model, HealthLynked is dedicated to securing a healthier future for generations to come, making each patient not only a beneficiary of this system but also a contributor to the global health community.

NOTE TO INVESTORS: The latest news and updates relating to HealthLynked are available in the company’s newsroom at https://IBN.fm/HLYK

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023
• The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases
• Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases

Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is continuing to make significant strides in the field of neurodegenerative diseases with its latest patent filings. The recent announcement is the filing of a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.

“The invention of a new solid form of our drug, buntanetap, and the subsequent patent filing represent groundbreaking milestones for our company,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis (https://ibn.fm/5vAuO). “This achievement will allow us not only to continue advancing our…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, has appointed a new member to its medical advisory board. According to the announcement, Mark Gilbert, MD, will be joining the board, bringing board membership to eight. A scientist emeritus at the National Institutes of Health (“NIH”), Gilbert served as chief of the neurooncology branch at NIH for a decade. During that time, Gilbert facilitated a team of laboratory and clinical investigators involved in groundbreaking research that advanced science in the brain tumor field. In addition to his experience at NIH, Gilbert practiced under world-renowned oncologist Dr. Alfred Yung, who is also a member of Calidi’s medical advisory board, MD Anderson in Houston; he also worked at UPMC in Pittsburgh, Emory University in Atlanta and Johns Hopkins in Baltimore. “We are honored that Dr. Gilbert has recognized the revolutionary science at Calidi Biotherapeutics in both tumoral and glioblastoma cancer treatment,” saidCalidi Biotherapeutics CEO Allan Camaisa in the press release. “He joins other luminaries on our medical advisory board who also believe in our stem-cell based therapy’s potential to offer hope and better results for those with cancer. . . . Dr. Gilbert’s expertise and experience will aid in guiding us on developing innovative, multi-institutional studies, partnering with national centers of excellence and key components of the NCI and NIH through Cooperative Research Development Agreements (‘CRADAs’) and other submissions. This will enable us to do some groundbreaking research to help people.”

To view the full press release, visit https://ibn.fm/TJuTU

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. For more information about the company, please visit www.CalidiBio.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Bluejay (NASDAQ: BJDX), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, recently announced the closing of a firm commitment underwritten public offering. Expected gross proceeds to the company were approximately $8.75 million. The base offering consisted of 5,368,098 common units or prefunded units, each unit consisting of one share of the company’s common stock or one pre-funded warrant to purchase one share of common Stock, two Class C warrants each to purchase one share of common stock and one Class D warrant to purchase such number of shares of common stock as determined in the Class D warrant. In addition, the company granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock and/or common warrants, representing up to 15% of the number of securities sold in the offering, solely to cover over-allotments, if any.

To view the full press release, visit https://ibn.fm/IrpOu

About Bluejay Diagnostics Inc.

Bluejay is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.Bluejaydx.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in tomorrow’s Virtual Investor Closing Bell Series. According to the announcement, CNS Pharmaceuticals CEO John Climaco will be presenting via a live video webcast at 4 p.m. on July 17. The presentation will include a corporate overview and will also feature a live question-and-answer period. A replay of the webcast will be available following the live presentation and will be accessible for 90 days.

To view the presentation, visit https://ibn.fm/Uy7c6

To view the full press release, visit https://ibn.fm/oHoJW

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug Administration (“FDA”) to transition to a new solid form of buntanetap in future clinical trials. “In June 2024, Annovis announced the filing of a composition of matter patent for the new crystal form of buntanetap and a provisional patent for the manufacturing process of this new form,” the announcement reads. “The company conducted comprehensive bridge studies in various solvents and in animals, comparing the old semi-crystalline form with the new crystalline form of buntanetap. Additionally, Annovis developed an innovative large-scale manufacturing process for the new form. This comprehensive data was submitted to the FDA for review.”

To view the full press release, visit https://ibn.fm/8LO9r

About Annovis Bio Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information on Annovis Bio, visit the company’s website at www.AnnovisBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Safety Shot (NASDAQ: SHOT) today announced its strategic partnership with KeHE Distributors, a leading natural and organic, specialty and fresh food distributor in North America. The collaboration expands Safety Shot’s presence to a broader audience and enhances consumer accessibility nationwide. Under the partnership, KeHE Distributors, renowned as one of the nation’s largest and most respected pure-play grocery and natural distributors, will play a pivotal role in ensuring that Safety Shot’s offerings reach more consumers efficiently and effectively. “We are excited to be joining forces with KeHE, whose large-scale network will be integral in helping to bring Safety Shot to the masses,” said Safety Shot’s Chief Revenue Officer Josh Wager. “This partnership will enable us to reach new heights in our distribution efforts, ensuring more consumers have access to Safety Shot. We look forward to a successful collaboration that benefits both of our companies and valued customers.”

To view the full press release, visit https://ibn.fm/XIodZ

About Safety Shot Inc.

Safety Shot, a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.

NOTE TO INVESTORS: The latest news and updates relating to SHOT are available in the company’s newsroom at https://ibn.fm/SHOT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes.

Nutriband’s proprietary AVERSA(TM) abuse deterrent transdermal technology works to incorporate aversive agents into transdermal patches that make an experience unpleasant, thereby discouraging abuse of substances. This technology is especially significant for drugs such as fentanyl, which have a high potential for abuse. The company’s lead product under development is AVERSA Fentanyl. Nutriband is working with Kindeva Drug Delivery to complete the scale-up of the commercial manufacturing process for AVERSA Fentanyl. The two companies started with a feasibility agreement and have since entered a commercial-development and clinical-supply agreement aimed at manufacturing product for a planned human-abuse potential clinical study, which is crucial for the New Drug Application (“NDA”) that the company anticipates submitting to the U.S. Food and Drug Administration. “AVERSA aims to ensure that these essential medications remain accessible to patients who need them while enhancing their safety profiles,” said the company in the press release. “The AVERSA technology is supported by a robust intellectual property portfolio, with patents granted in the United States and several other countries including Europe, Japan, Korea, Russia, Canada, Mexico and Australia. . . . The AVERSA(TM) trademark is integral to Nutriband’s platform technology, which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential.”

To view the full press release, visit https://ibn.fm/UWiO1

About Nutriband Inc.

Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products. The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) technology. This technology can be integrated into any transdermal patch to prevent the abuse, misuse, diversion and accidental exposure of drugs with abuse potential. For more information about the company, please visit www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease. This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubling since 1990.

The risk of developing this condition heightens with age; in addition, men are 50% more likely than women to develop the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Clene Inc. (NASDAQ: CLNN) are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, the successful in-vivo preclinical results are from SCNI’s innovative anti IL-17A/F VHH antibody fragment (“NanoAb”), which is being studied as a local, first-of-its-kind, intralesional biological treatment for from mild to moderate plaque psoriasis. An estimated million patients are diagnosed with plaque psoriasis in the United States, Japan and Europe. Scinai’s product candidate is designed to address the major shortcomings of currently available treatments. Testing confirmed the unique ability of Scinai’s NanoAb to neutralize both IL-17A and IL-17F isoforms and supported the concept that intralesional injection of a NanoAb blocking the IL-17 cytokine can impact the inflammatory cytokine cascade, leading to reduction in psoriatic lesion severity and improvement of the skin’s integrity. Based on the study results, Scinai plans to further refine dosing and drug half-life and then undergo a longer-duration, follow on in-vivo animal study later this year. “These positive results are very encouraging and mark a significant step forward in the development of a novel treatment for the underserved needs of the mild to moderate plaque psoriatic patients,” said Scinai Immunotherapeutics chief scientist Dr. Tamar Ben-Yedidia in the press release. “To date, most of the innovation related to treatment of autoimmune diseases has focused on drugs aimed at the more severe cases of these diseases, leaving milder cases mostly with generic topical drugs and phototherapy treatments. The mild psoriatic patients account for more than 50% of the plaque psoriatic patients and, while undertreated, they are prone to painful skin lesions sometimes in locations that generate a considerable disease burden for them. Scinai’s vision is to provide a highly efficacious, specific, convenient and safe local biologic treatment of plaque psoriasis lesions.”

To view the full press release, visit https://ibn.fm/CUJDA

About Scinai Immunotherapeutics Ltd. 

Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, derisked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique contract development and manufacturing organization (“CDMO”) providing biological drug development, analytical methods development, clinical cGMP manufacturing, and preclinical and clinical trial design and execution services to early-stage biotech drug-developmet companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will be participating in next week’s Emerging Growth Conference. According to the announcement, members of Clene’s management team will be presenting at the one-day conference, which is scheduled for July 18, 2024. The online presentation, which will begin at 4:45 p.m. EDT, will include a corporate update as well as a question-and-answer session. A webcast of the presentation will be available on the company’s website. The Emerging Growth conference is designed for public companies to present and communicate their new products, services and other major announcements to the investment community. The conference, which has an audience of potentially tens of thousands of individual and institutional investors, advisors and analysts, features companies from an array of growth sectors.

To view the presentation, visit https://ibn.fm/A52lW

To view the full press release, visit https://ibn.fm/nj6Iv

About Clene Inc.

Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, recognizes that successful treatment outcomes are largely dependent on the patient, with 90% of treatment success attributed to patient involvement. Patient engagement can lead to reduced hospitalizations as well as improve effectiveness, efficiency, quality of health services, quality of life, and responsiveness. “Astiva Health is leading the way in offering a Medicare Advantage Prescription Drug (‘MAPD’) health plan committed to reshaping the landscape of personalized and comprehensive healthcare by involving patients more completely in their own treatment,” a recent article reads. “The company is committed to encouraging and supporting effective communication between doctors and patients, knowing that this type of collaboration is essential to building trust, fostering a cooperative relationship, and ensuring patient engagement. In addition, Astiva Health is focused on providing tools that educate patients, ensuring that they are enrolled in appropriate care programs. The company also understands that continuous monitoring is a key component to successful healthcare, and Astiva Health offers a plan that facilitates this type of monitoring through primary care. Astiva cares about its members and works to establish lifelong relationships with members by providing a tailored approach to healthcare.”

To view the full article, visit https://ibn.fm/9bK9J

About Astiva Health

Astiva Health is a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan committed to redefining the standards of personalized and comprehensive healthcare. With a mission to elevate the well-being of individuals, Astiva Health specializes in innovative health plans tailored to meet the unique requirements of its members. The organization prioritizes a culturally responsive approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Astiva Health’s dedication to serving the underserved population is not only fulfilling a critical societal need but also positioning the company to tap into a market segment with significant growth potential. By addressing the diverse healthcare needs of its members, Astiva Health aims to create lasting relationships and contribute to the overall well-being of the communities it serves. Astiva Health invites individuals to join its transformative healthcare experience, where personalized care and lasting well-being take center stage. For more information about Astiva Health and enrollment details, please visit https://astivahealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva are available in the company’s newsroom at https://nnw.fm/Astiva

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Prostate cancer is challenging to treat, especially when the disease progresses to a castrate-resistant metastatic state. Conventional treatments, such as hormonal treatments, radiotherapy and chemotherapy, fail most times because of acquired resistance, off-target effects and toxicities.

It is well-known that amino acids perform important metabolic functions. While normal cells have lower demand for amino acids, cancer cells exhibit high demand for amino acids because of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

InMed (NASDAQ: INM) is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Degeneration (“AMD”) and its INM-901 small molecule drug candidate targeting Alzheimer’s disease (“AD”). “Recent preclinical data for INM-089 demonstrated significant functional and pathological improvements in an AMD disease model, indicating promising neuroprotective effects in the back of the eye… INM-901 is currently being investigated for its potential in treating Alzheimer’s disease. Recent preclinical data showcased its positive pharmacological effects, demonstrating reduced neuroinflammation and improved neuronal function, among other promising outcomes,” a recent article reads. “We are very excited with the data from recent preclinical studies demonstrating both significant functional and pathological improvements from INM-089 in the AMD model,” Dr. Eric Hsu, SVP of Preclinical Research and Development at INM, was quoted as saying. “The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD.”

To view the full article, visit https://ibn.fm/7sBHV

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with its subsidiary, BayMedica, InMed has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. It is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is in the process of submitting a briefing book to the U.S. Food and Drug Administration (“FDA”). The company anticipates submitting the book by July 13, 2024, in advance of the FDA granting a Type C interaction. According to the announcement, the purpose of the interaction between Clene and the FDA is to obtain key feedback on the potential path to submission of a new drug application (‘NDA’) for Clene’s CNM-Au8(R) as a potential treatment for ALS. The briefing book, which is focused on addressing comments from the FDA made in a December 2023 meeting, will contain analyses of data from completed clinical studies. “Clene believes these new analyses serve to further demonstrate the potential for CNM-Au8 as a treatment in people living with ALS, consistent with the accelerated approval standards,” said the company in the press release. “Clene also included data addressing the agency’s request to provide additional information concerning the relationship between CNM-Au8’s proposed mechanism of action and reduction in NfL, as well as the association between observed NfL reductions and improved clinical outcomes in ALS patients, including survival.”

To view the full press release, visit https://ibn.fm/PzwfB

About Clene Inc.

Clene and its wholly owned subsidiary, Clene Nanomedicine, is a late-clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. CNM-Au8 is a federally registered trademark of Clene Nanomedicine. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

On July 5,1994, Jeff Bezos founded Amazon as a bookselling business in his garage. Three decades later, Amazon is one the largest companies globally. The company’s value currently stands at $2.08 trillion.

Let’s look at the company’s trajectory, from the beginning to its current position in the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NextPlat Corp. (NASDAQ: NXPL, NXPLW) are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (“HLHS”) and Alzheimer’s disease, is announcing an addition to its board of directors. According to the announcement, senior healthcare investment banker Neha Motwani was elected to the board during the company’s recent Annual Meeting of Stockholders. Motwani brings more than two decades of experience to her new role as board member. Most recently she was managing director of healthcare investment banking at William Blair; she has also held a variety of roles at Truist Securities, Oppenheimer and Company, Stifel Financial, and Cowen and Company. “I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the board of directors,” said Longeveron cofounder, chief science officer and board chair Joshua Hare in the press release. “Her extensive knowledge of biopharma company operations, financing and capital markets will bring significant value to Longeveron as we continue to advance Lomecel-B(TM), our proprietary, scalable, allogeneic cellular therapy. With five positive clinical trials across three indications, we believe Lomecel-B has the potential to be an important therapy for some of the most difficult diseases and conditions associated with aging.”

To view the full press release, visit https://ibn.fm/VPNqZ

About Longeveron Inc. 

Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B(TM) has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. The Lomecel-B HLHS program has received three distinct and important FDA designations: Orphan Drug designation, Fast Track designation and Rare Pediatric Disease designation. To learn more about the company, visit www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

VolitionRx Limited (NYSE American: VNRX), a multi-national epigenetics company focused on saving lives and improving outcomes for people and animals with life-altering diseases, announced the engagement of PharmaVentures Ltd (“PharmaVentures”) to act as an advisor. PharmaVentures will provide strategic advice and transactional support as Volition works towards securing licensing deals with industry leaders for both Nu.Q(R) Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR(TM) – a novel detection method for liquid biopsy in cancer and potentially other diseases.

“PharmaVentures is a respected, international advisory company with a proven track record in licensing, partnering, and strategic alliances. PharmaVentures’ specialist experience in deal-making and extensive network means that it is ideally placed to support us as we seek to commercialize our potentially ground-breaking oncology and Capture PCR(TM) portfolio,” stated Gael Forterre, Chief Commercial Officer at Volition. ”We have a large amount of study data that we anticipate is close to being ready for inclusion in our data rooms and look forward to negotiating our first licensing deal in the human space.”

Adrian Dawkes, Managing Director, PharmaVentures, commented, “We believe Volition’s cutting-edge, epigenetic technology has the potential to significantly improve patient outcomes in the diagnosis and management of cancer patients and other diseases. Our role is to secure major licensing deals with key industry players and ensure Volition’s low-cost, simple blood tests are accessible worldwide. We are delighted to be supporting Volition in fulfilling its mission.”

To learn more about Volition and its technologies, please visit: www.Volition.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

IGC Pharma (NYSE American: IGC) today announced preclinical data demonstrating TGR-63’s potential as an effective treatment for Alzheimer’s disease. Analysis of the partition coefficient and mass spectrometry of brain tissue in Alzheimer’s murine models indicates that TGR-63 has the potential to cross the blood-brain barrier in humans. The findings build on earlier results demonstrating TGR-63’s efficacy in reducing amyloid plaque in Alzheimer’s mouse models. “These preliminary findings underscore TGR-63’s potential as a safe and effective treatment for Alzheimer’s disease,” said Ram Mukunda, CEO of IGC. “As we forge ahead with this amyloid-targeting drug, we are encouraged by its potential to offer an improved safety profile compared to currently approved treatments. This strategic approach should allow us to offer a diverse portfolio of Alzheimer’s-focused drugs that prioritize patient safety and efficacy. In addition to the focus on Alzheimer’s, we are training sophisticated AI models to analyze potential efficacy of targeting other receptors such as GLP-1, CB1, among others. We have four platforms, IGC-AD1, TGR, IGC-C, IGC-M and LMP. These platforms allow us to modify the core molecule and potentially target other receptors that could impact other diseases and conditions. We are very excited with the possibilities.”

To view the full press release, visit https://ibn.fm/A8hPT

About IGC Pharma Inc.

IGC is focused on Alzheimer’s disease, developing innovative therapies to address this devastating illness. The company’s mission is to transform the landscape of Alzheimer’s treatment with a robust pipeline of five promising drug candidates. IGC-AD1, with previously disclosed interim results, is in a Phase 2 clinical trial for agitation in dementia associated with Alzheimer’s (clinicaltrials.gov, NCT05543681). The remaining four molecules are in the pre-clinical stage of development. TGR-63 has been shown to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key hallmark of Alzheimer’s. IGC-1C targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer’s therapy. IGC-M3 aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer’s. LMP is designed to target multiple hallmarks of Alzheimer’s including plaques and tangles for a comprehensive approach to the disease. In addition to its drug development pipeline, IGC is attempting to harness the power of artificial intelligence to develop early disease detection models, optimize clinical trials, and explore new applications for its drugs.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has announced that four new executives will be joining the company’s management team. The four new leaders include Mark White as chief business officer; Alexander Morris, PhD, as director of strategic communications; Hilda Maibach as senior vice president of statistics; and Blake Jensen as head of quality. White is currently serving as a board member and has held positions of increasing responsibility at Pfizer, Bracco, Abbott and Bayer. Most recently, he was vice president of worldwide marketing at Pfizer, where he led global new product development, business development and in-line marketing for the Inflammation Therapeutic Area. Morin has garnered impressive experience in the science and communications space, specifically in the biopharmaceutical industry. He has served as an account executive at a boutique public relations firm, managing corporate communications strategies for a diverse range of clients, including early-to-late stage biotech companies, nonprofit organizations and large pharma clients. He also has rich experience as a consultant scientist. With more than three decades of experience in all aspects of clinical and observational studies in oncology, infectious disease, metabolic disorders and central nervous system disorders, Maibach brings invaluable expertise to the Annovis team. She has a background in supporting clinical trials with a focus on improving measurement sensitivity and innovating clinical trial design, data acquisition and management. She also has a keen sense of how to incorporate real-world evidence along with bioinformatics tools into clinical study design management to reduce costs and improve outcome reliability. Jensen has two decades of experience with contract service providers and emerging biopharma companies; he has also served as an investigator for the U.S. Food and Drug Administration. His expertise includes designing, building and implementing quality systems from scratch. He has facilitated teams across an array of sectors, including quality-risk management, global audits, vendor management, audit and inspection defense, policy and procedure management, billable audits and quality analytics. “We are delighted to have this strong group of individuals join the Annovis team,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD., in the press release. “Their expertise and leadership are critical in this pivotal moment in our company, as we continue making strides towards bringing buntanetap closer to NDA and to market for Alzheimer’s and Parkinson’s diseases.”

To view the full press release, visit https://ibn.fm/5pNSR

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit www.AnnovisBio.com.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will effect a 1-for-20 reverse stock split at 12:01 a.m. ET on July 11, 2024. According to the announcement, Clene’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 185634201 and the company’s existing symbol CLNN at the beginning of trading on July 11. The reverse stock split, for which Equiniti Trust Company LLC is acting as the exchange and transfer agent, is intended to enable Clene to regain compliance with the $1.00 minimum closing bid price required for continued listing on the Nasdaq Capital Market.

To view the full press release, visit https://ibn.fm/rnF4R

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

• For the first time in Medicare’s history, more than half of all eligible people with Medicare are enrolled in private Medicare Advantage plans
• Enrollment in Medicare Advantage programs is projected to grow from 54% of the eligible population in 2024 to 60% by the end of the decade
• Astiva Health has developed one of the most diverse networks in Southern California and offers a selection of benefits tailored to the specialized needs of its members

According to a recent KFF report, a record number of people enrolled in private Medicare Advantage plans last year (https://ibn.fm/YEpRJ). That trend bodes well for Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan that is committed to reshaping personalized and comprehensive healthcare.

“For the first time in Medicare’s history, more than half of all eligible people with Medicare, or 30.8 million people in 2023, are enrolled in private Medicare Advantage plans,” reported the KFF article. “Medicare Advantage plans are offered by private health insurance companies that receive payments from the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced its receipt of an updated non-binding letter of intent (“LoI”) from the European Investment Bank (“EIB”). The updated LoI outlines specific terms for converting the majority of the EIB’s loan into equity in the form of preferred shares, which are convertible into American Depositary Shares (“ADSs”) representing 19.5% of the fully diluted capital of the company at the time of closing. According to the announcement, the number of ADSs into which the preferred shares would be convertible would be fixed and without anti-dilution rights. The updated LoI does not require a variable remuneration, which in the previous LOI included 3% royalty on the company’s revenues and 5% of any equity raise up to a limit of EUR 70 million, nor does it provide for mandatory dividends or mandatory redemption. The amount of the loan that would be converted is approximately $28 million, while approximately $270,000 will stay as a loan payable on Dec. 31, 2031.

To view the full press release, visit https://ibn.fm/t2YtA

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The other business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech drug development programs. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

Glioblastoma multiforme is an aggressive cancer that grows quickly and spreads rapidly, originating as a growth of cells in the spinal cord or the brain. Researchers at the University of Copenhagen may have discovered how this type of cancer, which primarily effects adults, develops resistance to immunotherapy.

At first, the researchers thought that the cancer cells changed their DNA via mutation, helping them…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements, which are for the purchase and sale of 1,425,000 shares of common stock, are comprised of a registered direct offering and warrants. The offering and warrants are to purchase up to 1,425,000 shares of common stock in a concurrent private placement at a combined purchase price of $1.39 per share. The offering is expected to close today, subject to customary closing conditions, with gross proceeds estimated to reach about $1.98 million before deductions and expenses. CNS Pharmaceuticals plans to use the funds from the offering for working capital and general corporate purposes.

To view the full press release, visit https://ibn.fm/TYSIm

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has filed an amended and restated material change report. According to the announcement, the report amended the disclosure in Section 5.1 of the original MCR. “The amended and restated material change report is being filed to provide additional disclosure with respect of the private placement offering of Class A multiple voting shares of the company that closed on Dec. 5, 2023,” stated the company in the press release. “The amended and restated MCR can be found on the company’s SEDAR+ profile.”

To view the full press release, visit https://ibn.fm/ft6MF

About FSD Pharma Inc.

FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. FSD Pharma invented unbuzzd(TM) and spun out its OTC version to Celly Nutrition, a company led by industry veterans. FSD retains ownership of 25.71% of Celly Nutrition Corp. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd until payments to FSD Pharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, FSD Pharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. FSD Pharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical/medical uses. FSD Pharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property. For more information about the company, please visit www.FSDPharma.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

New research has determined that artificial intelligence (AI) models may be depending on “demographic shortcuts” when making medical diagnoses. Prior studies had determined that these models could reliably predict a patient’s race from their chest X-rays, something even the best radiologists couldn’t do.

This has been further put under the spotlight by this recent study, which determined that these artificial intelligence models have discrepancies in their…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Astrotech Corp. (NASDAQ: ASTC) are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN